Trial · NCT00109005
Adverse events84
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 84
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 1 | 8 | 2 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 1 | 9 | 1 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 2 | 8 | 2 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 2 | 9 | 3 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 1 | 8 | 1 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 0 | 9 | 0 |
| other | Alkaline phosphatase | Investigations | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 1 | 8 | 3 |
| other | Alkaline phosphatase | Investigations | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 3 | 9 | 3 |
| other | Constipation | Gastrointestinal disorders | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 1 | 8 | 1 |
| other | Constipation | Gastrointestinal disorders | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 0 | 9 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 1 | 8 | 4 |
| other | Diarrhea | Gastrointestinal disorders | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 2 | 9 | 3 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 2 | 8 | 4 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 0 | 9 | 0 |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 7 | 8 | 14 |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 3 | 9 | 9 |
| other | Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L) | General disorders | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 2 | 8 | 2 |
| other | Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L) | General disorders | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 2 | 9 | 5 |
| other | Flu-like symptoms | General disorders | Cohort 1 - 25 mg Lenalidomide (Revlimid) | 1 | 8 | 4 |
| other | Flu-like symptoms | General disorders | Cohort 2 - 5 mg Lenalidomide (Revlimid) | 0 | 9 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00109005/events